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Since the description of a case with "diffuse encephalitis with sclerosing inflamma- 
tion of the hemisphere white matter" by Bodechtel and Guttman (1), there have been 
numerous reports that have indicated that measles virus is associated with this disease. 
Subacute  sclerosing panencephalitis (SSPE) I  occurs mostly in  children and  young 
adults as a  slow progressive inflammatory disorder of the central nervous system (2). 
There have been reports that the SSPE virus is not identical (3, 4) to the wild or at- 
tenuated strain of the measles virus. One characteristic laboratory finding in clinical 
cases of SSPE has been the presence of high concentration of measles antibody levels 
in the serum and spinal fluid of nearly all known cases of this progressive neurological 
disease (5, 6). Still, the presence of these high levels of humoral antibody does not alter 
the course of the disease in patients with SSPE. Horta-Barbosa et al. (7) have isolated 
the measles virus in mixed cultures of lymph node cells and HeLa cells and identified 
it  by  hemagglutination  inhibition,  immunofluorescence,  and  neutralization  tests. 
Dayan and Stokes (8) identified measles virus antigen by immunofluorescence in cells 
from cerebrospinal fluid in four patients with SSPE. 
Immunologic abnormalities have  been  reported  (9,  11)  in  patients  with  SSPE. 
Saunders et al. (12)  studied the in vitro response of an 8~i-year old boy with SSPE 
to measles antigen and found specific immunocompetent lymphocytes in the patient 
and postulated that the destructive interaction between such lymphocytes and host 
cells in the brain may lead to SSPE. Mizutani et al. (13)  confirmed the presence of 
cellular immunity to measles antigen in a 9-year old girl with SSPE, using skin testing 
and macrophage migration inhibition as an index. On the other hand, Moulias et al. 
(14) tested 20 cases of SSPE and found that none of them responded to measles antigen 
as judged by blastic transformation and leukocyte migration tests. Lischner et al. (15) 
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found results similar to that of Moulias et al. (14). Dayan and Stokes (16) and Philips 
(17) state that antigen-antibody  complexes might be involved in the pathogenesis of 
the disease. 
Gatti (18) has reviewed the presence of inhibitory  factors that have been detected in 
the serum and plasma of patients with a wide range of disorders. He found inhibitors  of 
allogeneic lymphocyte responses to PHA in the plasmas of  16 of 21  patients with 
various forms of nonlymphoid malignant disease,  including two of five with breast 
cancer. Plasma inhibitors have been reported in diseases like ataxia telangiectasia (19) 
and multiple sclerosis (20). 
Scheurlen et al. (21) characterized an inhibitor  present in the plasma of patients with 
Hodgkin's disease and cancer. This plasma inhibited specific lymphocyte transforma- 
tion with tuberculin and also nonspecific stimulation by agents such as phytohemag- 
glutinin  in normal donors. Allen et al. (22) described a labile inhibitory  factor of mito- 
gen-induced lymphocyte transformation in the fresh plasma of a  patient in stage 3 
of SSPE. 
In the present study, using the migration inhibition test,  the  lymphocyte 
transformation and the lymphotoxin assays, we found that plasma and spinal 
fluid from four cases of SSPE blocked the in vitro response of their lympho- 
cytes to measles-like virus isolated from a known case of SSPE. This blocking 
was not seen by the use of measles sero-negative plasma. Attempts were made 
to characterize this blocking factor. 
Materials and Methods 
Measles Antigen--Measles  virus  vaccine, live attenuated  (Schwaxz strain),  which was 
from a chick embryo tissue culture (Bio no. 185, Dow Chemical Co., Indianapolis, Ind.), was 
used initially as a source of antigen. This vaccine was also used after autoclaving at 121°C 
for 30 min. Both the antigens were dialyzed with 200 X  volume of 0.15 M NaC1 before use 
to remove preservatives. The suspension was diluted with RPMI 1640 medium containing 
penicillin, 100 U/ml; streptomycin,  100/zg/ml  and 200 mM L-glutamine (all from Grand 
Island Biological Co., Grand Island, N. Y.). Live measles virus isolated from a known case 
of SSPE was prepared by Dr. L. Horta-Barbosa, National Institute of Mental Health, NIH, 
Bethesda, Md., by the following procedure. This virus was passaged three times in approxi- 
mately 10  ~  "7 HeLa cells with a multiplicity of -4- two infective particles per cell. After adsorp- 
tion for 1 h at 37°C, the infected HeLa cells were suspended in 500 ml Joklik medium en- 
riched with penicillin 75 U/ml, and streptomycin 50 U/ml, with 5% fetal bovine serum, and 
cultivated in suspension (stirring flask) at 37.5°C. Samples of this culture were analyzed daily 
for hemaggiutinins. After 6 days, the hemagglutinin (HA) titer was 1:128. The culture was 
then frozen and thawed twice and clarified by centrifugation  (200 rpm for 30 rain). The in- 
fective titer of this preparation  was 106"5/ml. This antigen preparation  was  concentrated 
100 X  by centrifugation as follows: 6% gelatin (1 ml per 100 ml of  antigen preparation) 
was initially added, and the material was centrifuged at 30,000 rpm for 90 min in a Spinco 
Model L ultracentrifuge (Beckman Instrument Co., Inc., Palo Alto, Calif.). The sedimented 
material was resuspended in Hank's media containing penicillin and streptomycin to 1~ 0 the 
initial volume. This procedure was repeated to achieve a 100 X  antigen concentration. This 
concentrate was frozen and thawed three times and centrifuged at 1,500 rpm for 10 min to 
remove the gelatin and cellular del)ris. The hemagglutinin titer of this 100 X  antigen con- 
centrate was 1:12,800. 
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Naval Hospital, Bethesda, Md., and by Dr. Dale E. Dietzman, NIMH, NIH. An ultraviolet 
treated measles virus vaccine was supplied by Dr. Jeffrey Allen, NIMH, and was used in one 
of the experiments as a source of antigen. Hemagglutination, complement fixing gel immuno- 
precipitation, and hemagglutinin inhibition titers were determined on the serum and spinal 
fluid of the patients and control subjects used in this investigation. 
Preparation of Leukocyte Suspensions--Blood  was  drawn  from  the patients and  control 
subjects in sodium heparin (preservative free, Medical Chemicals Corporation,  Chicago,  Ill.) 
and allowed to settle in the syringe in the inverted position. Leukocyte-rich plasma was drawn 
off and centrifuged at  150 g for 15 min. The plasma was saved, and the cells washed two 
times with 50 volumes of the media, counted by means of an Autocytometer (Autocytometer 
II, Fisher Scientific Co., Pittsburgh, Pa.) and resuspended to 107 cells/ml. 
The Migration Inhibition Test--This was performed essentially according to the method of 
David and David (23) with a few modifications. Peripheral leukocytes from the patients, the 
positive control and the negative control, were washed and resuspended in media to contain 
3  X  106 leukocytes/ml. Measles antigen in various concentrations was then added. Control 
cultures received either media or the supernates of uninfected HeLa cell cultures. Lympho- 
cyte cultures were incubated for 48-72 hr in 2-ml suspensions in 15 X  75-mm snap-top cul- 
ture tubes (Falcon Plastics, Oxnard, Calif.) at 37°C in a 5% CO2, humidified air atmosphere 
Cultures were centrifuged and the superuatant fluid collected. Macrophages obtained by oil 
induction from guinea pigs were loaded into plain, blue tip, 75-mm capillary tubes sealed at 
one end.  This was accomplished by means of a  Hamilton repeating dispenser and syringe 
unit  (Lawshe Instruments  Company,  Bethesda,  Md.)  and  a  sterile,  disposable,  26  gauge 
spinal needle (Becton, Dickinson & Co.,  Rutherford,  N.  Y.),  such that each capillary con- 
tained 50 #1 of macrophage suspension containing 50 )< 106 cells/ml. The capillary tubes were 
centrifuged at 150 g for 10 min and the capillary tube cut at the cell fluid interface. The short 
piece of capillary tube was affixed  to the inside of a migration inhibition chamber (Mini Lab 
Co., Ville De Laval, P.Q., Canada) with silicone grease.  Each chamber contained two tubes 
and was sealed ~t the top by means of a cover slip and silicone. Fluid (0.5 ml) from the lympho- 
cyte cultures was ~ected into the sealed chambers by means of a  tuberculin syringe.  The 
injection ports were  sealed  with plastic tape  to  prevent evaporation.  The chambers  were 
incubated at 37°C for 24-48 h. The image of the cover slip, capillary, and cell sheet was pro- 
jected by means of a Bausch and Lomb projecting prism (Bausch and Lomb, Inc.,  Rochester, 
N. ¥.)  onto a  sheet of paper and the outline of the migrated cells was traced. The area  of 
migration was determined by planimetry and the percent migration inhibition was determined 
by the following formula: 
Average area of migration with antigen 
% migration inhibition =  1 -  X  100. 
Average area of migration without antigen 
A  second method for determining production of migration inhibition factor  (MIF)  was 
also employed. This consisted of adding 1 vol of  the leucocyte suspension (10 X  106 cells) 
from the patient to 1 vol of guinea pig macrophage suspension (30 X  106/ml). This mixture 
was loaded into capillary tubes and placed into the chambers as previously described. Instead 
of adding the superuates of lymphocyte cultures, antigen suspensions of various dilutions in 
media were added to the chambers. Migration inhibition was determined after 18-24 h. 
The Lymphocyte Transformation Test:--Leukocyte suspensions in media were layered onto 
Ficoll-hypaque gradients (sp gr 1.078)  and centrifuged at 400 g for 45 min according to the 
method  of  Boyum  (24).  The lymphocyte-rich band was  aspirated  by means  of  a  pasteur 
pipet and washed with 50 vol of media. The cells were resuspended to 2  X  106/ml in media 
containing either  15%  autologous  or homologous plasma.  The lymphocyte transformation 
test was performed using either the virus suspensions or SSPE virus infected HeLa cells as 
described in a previous report (25). AtI~EI~  ET  AL.  905 
When virus suspensions were used, 100 #1 of the lymphocytes (2 X  10S/ral) were added to 
each well of a  microtiter plate and  50 #1 of varying concentrations of the virus suspension 
added.  Control wells received media. Sero-positive, sero-negative, and patients' plasma were 
added in varying concentrations ir~ 50 gl. 
Triplicate cultures were prepared in Microtest II microtiter plates (Falcon Plastic). Rapid 
dispensing  of  lymphocytes,  cultured  cells and  culture  additives  were  accomplished  with 
Hamilton repeating dispensers  (Hamilton Company,  Reno, Nev.). Cultures were incubated 
72 h  at 37°C in a 5% COs humidified a~mosphere.  18 h before harvesting, 0.02 ml of RPMI 
1640 containing 1 #Ci of [methyl-SH]thymidine (sp act  1.9  Ci/mmol, Schwarz Mann,  Div. 
Becton, Dickinson & Co., Orangeburg, N. Y.) was added. Harvesting was accomplished using 
a  multiple automated  sample harvester  (MASH)  as previously described  (26-28)  and  the 
tritiated thymidine incorporation was determined by scintillation spectrophotometry.  Data 
from the scintillation counter was recorded on paper tape and analyzed using a Wang 700C 
advanced programming calculator (Wang Laboratories, Inc., Tewksbury, Mass.). 
Lymphotoxin Assay.--Sensitive  lymphoid cells in the presence of the sensitizing antigen 
or normal cells, when cultured with nonspecific mitogenic agents,  cause  lymphocyte  trans- 
formation.  The cell-free medium  of such  activated  cultures  has  been shown  to possess  a 
lymphokine-termed  lymphotoxin  (LT)  (29).  LT  activity  has  been  demonstrated  by  the 
ability of cell-free supernatant  fluids  to cause the destruction of mouse "L" fibroblasts, and 
the secretion of LT has been shown to be a  thymic-dependent function  (30).  This lympho- 
toxin assay was performed using a  new microassay system. 2 In this assay system,  the LT 
activity was measured as  the decrease in the uptake  of [3H]thymidine  by L  cells.  Briefly, 
lymphocytes from the sero-negative controls,  the sero-positive controls,  and  the SSPE pa- 
tients (2 X  106/ml), in a total volume of 5 ml in 15% autologous or 15% sero-negative plasma 
and 1% final concentration of SSPE virus, were incubated at 37°C, 5% CO2, 95% humidified 
air for 72 hr. Supernatant fluid from these cultures was used for the lymphotoxin assay. The 
IDs0 levels of lymphotoxin activity were calculated as the dilution of the supernatant  fluid 
being tested for LT activity which gave 50% of the counts per minute of the media control 
values. HeLa cells were similarly used as another source of target cells for the LT assay. 
Characterization of the  Blocking Factor.--Plasma from  SSPE  patients  (1  ml  each)  was 
treated  by standard  biochemical techniques with various enzymes such as neuraminadase, 
ribonuclease, and  deoxyribonuclease. The enzyme-treated  plasma was centrifuged at  600 g 
and  the supernatant  fluid was passed  through  a  0.22 #  Swinnex filter separately and  each 
tested for its ability to block the in vitro response of leukocytes from patients with  SSPE 
in the presence of 1% SSPE virus suspensions.  1-ml samples of SSPE plasma were also treated 
with trypsin-EDTA and  0.1  M  2-mercapto-ethanol,  dialyzed, filtered, and  used as above. 
Ammonium sulfate precipitation was carried out on SSPE plasma and  three cuts were ob- 
tained, the 0.25%, 25-50%, and  >  50% fractions. These were also dialyzed and filtered be- 
fore use. 
Plasma and spinal fluid from the SSPE patients were applied to a G-200 Sephadex ascend- 
ing column and  three major fractions collected. Using markers of known molecular weight, 
peak A of both the plasma and spinal fluid was judged to have a tool wt greater than 150,000. 
Other Antigens Used.--To  test for specificity of the blocking factor, other viral and bac- 
terial agents were used. These consisted of cytomegaiovirus suspension grown in WL38 cell 
line,  PPD,  histoplasmin,  Streptokinase  Streptodornase,  tetanus  toxoid,  mumps,  and  vac- 
cinia vaccines. All the antigens Were dialyzed against RPMI 1640 media to remove preserva- 
tives before use. 
Knudsen,  R. C., A. Ahmed, and K. W.  Sell.  1974. A microassay for lymphotoxin using 
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RESULTS 
Serology:--The diagnosis of SSPE was made clinically in all four cases stud- 
ied, and supported by the finding of significant antimeasles  titers  in both the 
serum and cerebrospinal fluid. The case histories and clinical findings will be 
discussed  in  a  separate paper.  M.  C.  and  R.  S.  were patients  at  the Naval 
Hospital, T.  C. was a patient  at  the Clinical  Center,  NIH, and S.  O. was a 
patient at St. Vincent's Hospital, New York. 
M.  C., T. C., and S.  O. were in stage 3 of SSPE when these studies began, 
whereas R. S. was in stage 1 at the beginning of the study and progressed to 
stage 3  during  the  course of this investigation.  The measles  antibody  titers 
are seen in Table I. All of them were confirmed to be rubeola specific by gel 
immunoprecipitation.  The positive controls used in  these studies  (J.  W.  and 
S. P.) had antimeasles titers of 1:128. The negative controls (A. A. and B. B.) 
had no measles antibody titers  (< 1:10)  by either complement fixation, hem- 
agglutination inhibition,  and gel immunoprecipitation techniques.  Spinal fluid 
used as a control (J. M.) was obtained from a normal healthy volunteer which 
also had a negative titer against measles. In some cases, the  spinal  fluid  titer 
was higher  than  the serum titer,  which  is unusual,  but  the  assays were per- 
formed on different days.  In general, if performed together,  the  titer was al- 
ways higher in the serum. 
Migration Inhibition Test.--Various antigen preparations were tried to deter- 
TABLE I 
Measles Antibody Titers in the Serum and Spinal Fluid of Four Cases of SSPE 
Patient  Date performed 
Reciprocal of the antibody titer* 
Serum  Spinal fluid 
M.C.~.  9/27/71  256  256 
10/10/71  256  256 
5/12/71  1,024  128 
T.C.§  2/11/71  512  128 
R.S.~  4/24/72  32  32 
5/02/72  128  256 
5/15/72  128  2,048 
5/31/72  128  2,048 
6/12/72  512  1,024 
s.o.ll  8/29/72  >2,048  16 
10/27/72  ND  4 
2/21/73  > 128  16 
3/05/73  >8,000  32 
* Serum and antibody titers determined by complement fixation test and confirmed to be 
rubeola specific by gel immtmoprecipitation techniques. 
:~ Patients  at the National Naval Medical Center, Bethesda, Md. 
§ Patient at the Clinical Center, NIH. 
[[ Patient at St. Vincent's Hospital, New York. Att~ED  ET  AL.  907 
mine which would give optimal results in vitro.  Commercial, live attenuated 
vaccine was dialyzed against  200  ×  of 0.15  M  sodium chloride and  concen- 
trated by means of an Amicon UM-2 membrane filter Amicon Corp.,  Lexing- 
ton, Mass. Either the dialyzed preparation or a dialyzed, autoclaved prepara- 
tion (121°C, 30 min) were used undiluted or diluted in media to a final concen- 
tration of 1 : 10, 1 : 100, or 1 : 1000. The results of the MIF assays were obtained 
using  these  two  preparations  and  the  SSPE  virus  (courtesy of Dr.  Horta- 
Barbosa, NIMH). Cells used in these tests were obtained from one SSPE pa- 
tient  (M.  C.),  and  one positive control  (J.  W.),  and  two  negative  controls 
(A.  A.  and B.  B.). Table II shows a  comparison between two types of MIF 
assays used. It can be seen that the SSPE patient and the sero-positive con- 
trol produce MIF in the presence of a 1 : 100 dilution of SSPE virus and a 1 : 10 
dilution of the autoclaved, dialyzed measles vaccine (ADV). The sero-positive 
control also produced MIF in the presence of a  1 : 100 dilution of the ADV in 
the direct assay but not in the indirect assay,  indicating an increased sensi- 
tivity of the direct assay. Both sero-negative controls showed lack of reactivity 
to either antigen preparations. ADV, used in similar concentrations, produced 
negative  results.  The ADV  was  unstable  in  storage  and  gave  inconsistent 
results  upon  repeated  testing.  Therefore,  the  SSPE  virus  preparation  was 
used  for subsequent  experiments  at  a  final  concentration of  1:100  (1%)  in 
media. 
Since the direct assay was more consistent and produced results in a shorter 
TABLE  II 
Effects of Various Measles Antigen Preparation on the Direct and Indirect Migration Inhibition 
Assays 
% Migration inhibition* 
M. C. cells~  J.W. cells§  B.B. cellsl]  A.A. cellsU 
Indirect¶  Direct**  Indirect  Direct  Indirect  Direct  Indirect  Direct 
SSPE virus 
1:100  83  72  95  94  2  7  10  12.5 
1:1000  6  3  11  32  9  6  0  1.5 
Autoclaved, dialyzed 
measles vaccine 
1:10  95  61.5  93  77  0  0  ND 
1:100  2  4.5  4  98.5  0  0  ND 
1:1000  0  0  0  19.5  0  0  ND 
Average area of migration with antigen 
* %  Migration inhibition =  1 --  X  100. 
Average area of migration without antigen 
M. C. SSPE patient. 
§ J. W., sero-positive measles control. 
]I B. B. and A. A., sero-negative measles control, 7 mo baby and adult, respectively. 
¶ Indirect assay using supernatant fluid from lymphocyte-viral antigen culture. 
** Direct assay using lymphocyte-macropbage migration in culture with viral antigen. 908  BLOCKING  FACTORS  IN  SSPE  PATIENTS 
period of time than the indirect assay, it was used throughout the remainder 
of the investigation. 
Since the SSPE patients were demonstrating good in vitro cellular reactivity 
by the production of MIF in response to 1% SSPE virus and also had signifi- 
cant  amounts  of antimeasles  antibody titers both in  their serum  and  spinal 
fluid, it was  decided to search for factors that would give  rise  to  abnormal 
cellular reactivities in vivo. Since all the MIF tests were run in media or media 
with fetal calf serum, it was the purpose of the next experiment to determine 
the effect of SSPE plasma and spinal fluid in the MIF test. Figs. 1 and 2 show 
the results of  the use of various concentrations of SSPE  plasma  and  spinal 
fluid  on  the  production of MIF  by leucocytes from  R.  S.  (SSPE  patient), 
measles  sero-negative  and  measles  sero-positive  controls.  The  sero-negative 
cells showed negligible MIF production in the presence of either SSPE plasma 
or spinal  fluid. The patient's  cells  (R.  S.)  and the sero-positive control cells 
(S.  P.) produced MIF in the presence of various concentrations of sero-nega- 
tive plasma but demonstrated a marked decrease in response upon  increasing 
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FIG. 1.  Effect  of varying concentrations  of plasma from a measles sero-negative and a 
patient  with  SSPE on  the release of  migration inhibition factor by ]ymphocytes in  re- 
sponse to 1%  SSPE virus. (A--A), measles sero-negative lymphocytes response; (0--0), 
measles sero-positive  lymphocyte  response;  (I---m),  SSPE  patient's  (R.  S.)  lymphocyte 
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FIG. 2.  Effect of varying concentrations of spinal fluid from a measles sero-negative and a 
patient with  SSPE  on  the  release of migration  inhibition factor  by lymphocytes in re- 
sponse to  1% SSPE virus.  (&--A), measles sero-negative lymphocyte response; (e--O), 
measles sero-positive lymphocyte response; (E--i), SSPE patient's (R. S.) lymphocyte re- 
sponse. 
concentrations of SSPE plasma (Fig. 1). The production of MIF was completely 
blocked at concentrations of SSPE plasma higher than 8 %. When spinal fluid 
was tested for such "blocking factors", it was found (Fig. 2) that cells from the 
SSPE patients and sero-positive cells  again showed decreased  production  of 
MIF with increasing concentrations of SSPE spinal fluid. This blocking factor 
was not found in normal  (J.  M.)  spinal fluid. Generally, the amount of the 
blocking factor was in higher concentration in the SSPE spinal fluid than in 
the SSPE plasma. 
In efforts to determine whether this type of blocking factor occurs in the 
plasma of other  cases of SSPE,  the  experiment  was repeated using various 
concentrations of plasma  and  spinal  fluid from other  SSPE  cases  studied. 
Tables III and IV show that such a blocking factor also occurs in plasma and 
spinal fluid of all of the SSPE  cases studied but does not occur in measles 
sero-positive plasma and spinal fluid as demonstrated by the response of both 
the SSPE cells and the sero-positive cells. The sero-negative cells did not pro- 
duce MIF. This showed that the blocking factor in the SSPE plasma and spinal 910  BLOCKING  FACTORS  IN  SSPE  PATIENTS 
TABLE III 
Inhibition  of Release of Migration Inhibition  Factor by  Cells from Patients with SSPE by 
Their Plasma 
Plasma concentration  Control 
% Migration inhibition* 
Negative:[:  Positive§ 
M.C.II  R.S.][  T.C.II  S.O.]l 
1% control negative  1.9  59.4  53.7  72.4  69.8  59.8 
10% control negative  4.4  53.7  81.3  81.6  74.4  64.6 
25% control negative  5.7  64.5  80.4  69.4  60.7  51.8 
1% control positive  5.3  51.8  ND  56.9  ND  52.7 
10% control positive  4.9  55.7  ND  64.1  ND  61.1 
25% control positive  9.8  68.4  ND  59.8  ND  58.3 
1% M.C.  8.5  53.4  87.1  85.5  52.3  64.8 
10% M.C.  2.8  14.0  14.7  --0.8  4.1  --3.3 
25% M.C.  3.6  4.1  11.2  4.6  --7.8  6.4 
1% R.S.  7.8  44.1  54.9  56.6  66.6  61.7 
10% R.S.  5.9  8.4  12.8  5.1  5.8  8.8 
25% R.S.  11.3  1.7  --0.9  --3.7  11.4  4.0 
1% T.C.  4.1  ND  49.4  64.3  47.9  ND 
10% T.C.  5.3  ND  8.4  13.8  12.6  ND 
25% T.C.  11.1  ND  12.9  2.2  7.3  ND 
1% S.O.  3.7  ND  ND  ND  ND  77.1 
10% S.O.  2.1  ND  ND  ND  ND  15.3 
25% S.O.  --0.8  ND  ND  ND  ND  --0.2 
* %  Migration inhibition =  1 --  Average area of migration with antigen 
Average area of migration without antigen 
:~ A. A., measles sero-negafive donor. 
§ S. P., measles sero-posifive donor. 
I] M. C., R. S., T. C., and S. O., clinically diagnosed cases of SSPE. 
X  100. 
fluid was cross-reactive in its effect on cells from either SSPE patient or measles 
sero-positive controls° 
Lymphocyte  Transformation  Test:--Purified  peripheral  blood  lymphocytes 
from R. S. (SSPE patient) showed a significant response to SSPE virus-infected 
HeLa  cells (Tables V  and  VI).  R.  S.  lymphocytes cultured with noninfected 
HeLa  cells gave  354  (4-20)  cpm.  When  cultured  with  SSPE  virus  infected 
cells, they produced 4,656  (4-1197)  cpm,  which  gives a  stimulation index of 
13.9. When 10% R. S. plasma (Table V) or 1% R. S. cerebrospinal fluid (Table 
VI) was present,  the response dropped to control values indicating a  blocking 
of the blastogenic response of the lymphocytes. 1% R. S. plasma (Table V) or 
0.1%  R.  S. cerebrospinal fluid  (Table VI)  was not sufficient to eliminate the 
response. 
In  the  MIF  results  on  these  same  individuals,  the  measles  sero-positive 
control  (S.  P.),  as well as the SSPE patient, produced MIF  when  exposed to 
the purified SSPE virus. However, Table V  indicates that in this transforma- AIIMED  ET AL.  911 
TABLE IV 
Inhibition  of Release of Migration Inhibition  Factor by Cells from Patients  with SSPE by 
Their Cerebrospinal Fluid 
% Migration inhibition* 
Spinal fluid  Control 
concentration  M.C.][  R.S.I]  T.C.]]  S.O.I] 
Negatlve~  Positive§ 
0.1% J.M.  5.8  43.6  50.1  34.9  42.8  47.5 
1% J.M.  9.1  49.8  56.4  51.1  56.9  64.3 
10% J.M.  8.1  40.4  44.7  49.6  48.3  56.9 
0.1% M.C.  2.7  49.6  52.8  56.7  41.8  39.9 
1.0% M.C.  5.1  11.3  5.8  9.6  8.7  1.8 
10% M.C.  4.8  4.6  4.4  11.4  9.3  --2.8 
0.1% R.S.  5.1  38.5  55.3  47.5  ND  53.7 
1.0% R.S.  9.9  2.1  7.7  -16.5  ND  2.8 
10% R.S.  5.3  0.8  1.1  1.4  ND  4.9 
0.1% S.O.  4.1  ND  ND  ND  ND  49.9 
1.0% S.O.  3.7  ND  ND  ND  ND  2.7 
10% S.O.  9.2  ND  ND  ND  ND  -5.9 
* % Migration inhibition in response to 1% SSPE virus  = 
Average area of migration with virus 
1- 
Average area of migration without virus 
~t A. A., measles sero-negafive control. 
§ S. P., measles sero-posifive control. 
I[ M. C., R. S., T. C., and S. O., four cases of SSPE. 
¶ J. M., healthy human volunteer. 
X  100l 
tion  test,  the  measles  sero-positive  lymphocytes did  not  show  a  blastogenic 
response  to the  SSPE virus infected  HeLa cells,  whereas  the  SSPE patient's 
lymphocytes did. None of the lymphocytes responded to the noninfected HeLa 
cells,  and  the blastogenic responses  to 0.1%  PHA-P of lymphocytes from all 
SSPE patients and controls were within the normal range. 
These results were confirmed using lymphocytes from another SSPE patient 
(S. O.). Lymphocytes from S. O. cultured with noninfected HeLa cells gave 599 
(-t-66) cpm (Tables V and VI). When cultured with SSPE virus infected HeLa 
cells,  they responded  with  7,571  (4-291)  cpm,  giving  a  stimulation  index  of 
12.6.  Again,  10%  plasma or 1%  cerebrospinal  fluid from S.  O. was sufficient 
to nullify the blastogenic response. No response to noninfected HeLa cells was 
seen, and the nonspecific (PHA-P) mitogenic responses were within the normal 
range. 
Lymphotoxin  Assay:--This  microlymphotoxin  assay uses  only 0.05  ml  of 
supernatant  fluid  of lymphocyte cultures.  Supernatant  fluids  from activated 
lymphocyte cultures were tested for LT activity using L  cells and HeLa cells 
as target cells. When lymphocytes from SSPE patients  and measles sero-posi- 
tive  controls  were incubated  with  1%  SSPE virus  suspensions  for 48 h,  low 912  BLOCKING  FACTORS  IN  SSPE  PATIENTS 
TABLE V 
Inhibition of Lymphocyte Response to SSPE Virus Infected HeLa Cells by Plasma from Patients 
with SSPE 
Lymphocytes* 
None 
Control 
negative[[ 
Control 
positive¶ 
R. S. ~ 
S. O. ** 
Concentration of plasma 
10% control negative 
10% control negative 
10% R. S. 
lO% s. o. 
10% control negative 
10% control positive 
10% R. S. 
1% R. S. 
10% control negative 
10% control positive 
to% R. S. 
Uptake of [gH]thymidine (cpm ~  SE) 
0.1% PHA-P:~ 
50976  ±  5127 
63918 ±  6043 
49498 ±  4351 
55984 ±  6359 
42975 ±  3723 
56385 ±  4810 
48193 ±  5331 
56616 ±  4218 
43388 ±  4481 
ND 
59139 ±  4813 
SSPE virus in- 
fected HeLa cells 
320  ±  100 
281  ±  71 
356  ±  28 
429  ±  34 
327  ±  27 
174  ±  19 
331  ±  18 
153  ±  32 
443  ±  56 
4656 ±  1197 
ND 
225  ±  61 
Noninfected 
HeLa cells§ 
227  ±  26 
397  ±  18 
411  ±  29 
396±  36 
138  ±  18 
287  ±  18 
ND 
ND 
ND 
334  ±  28 
ND 
308  ±  27 
1% R. S. 
10% control negative 
10% control positive 
10% R. S. 
10% S. O. 
1% S.O. 
453199 ±  3124 
92184 ±  5918 
101563 ±  7271 
88591 ±  4289 
123141 ±  9346 
94333 ±  5120 
5609 
7571 
7735 
412 
230 
7638 
+  280  460  ±  41 
-4- 291  588  :~  65 
±  440  511  ±  29 
±  59  548  +  46 
±  25  539  ±  141 
±  294  384  ±  31 
* 200,000 lymphocytes per 0.2 ml culture. 
:~ Final concentration of phytohemagglutinin-P in each culture measles. 
§25,000 HeLa cells (treated with mitomycin-C) per 0.2 ml culture. 
[I Measles sero-negative donor. 
¶ Measles sero-positive donor. 
** SSPE patients. 
levels of LT were obtained (IDs0 range from 1:2 to  1:4.5) by both cell types 
but only in measles sero-negative plasma.  SSPE  plasma completely blocked 
the  production  of  LT.  Measles  sero-negative lymphocvtes did  not produce 
any LT in response to the SSPE virus. 
When SSPE virus infected HeLa cells were used as a  source of antigen, in- 
terestingly, much higher levels of LT (1:12 using HeLa  target cells and  1:32 
using L  target  cells)  were produced by lymphocytes from  SSPE  patients in 
10 % measles sero-negative plasma. This response was again completely blocked 
using 10%  SSPE plasma  (Table VII).  This data  clearly shows  that plasma 
from  SSPE  patients blocks the  production of LT by SSPE  lymphocytes by 
both direct activation by the virus or by the use of SSPE viral infected HeLa 
cell and lymphocyte cell coculture techniques. 
Characterization  of the Blocking  Factor:--Plasma  from  a  SSPE patient was AI=I2"~ED ET  AL.  913 
TABLE  VI 
Inhibition of Lymphocyte Response to SSPE Virus Infected HeLa Cells by Spinal Fluid from 
Patients with SSPE 
Final concentration  of  Lymphocytes*  spinal fluid 
Uptake of [aH]thymidine (cpm =t= SE) 
SSPE virus infected  Noninfected 
HeLa cells$  HeLa cells$ 
None  361  4.  43  389  4.  22 
0.1% J.M.§  289  -4-  24  312  4.  53 
1.0% J.M.  573  +  12.5  288  4.  38 
Control negative[[  cell  0.1% R.S.  434  -4-  19  239  4.  11 
1% R.S.  479  4.  33  615  4.  69 
1% S.O.  440  4-  36  543  4.  44 
0.1% J.M.  4,818  -4-  239  512  4.  46 
R. S.¶ cells  1% J.M.  4,656  -4-  1197  334  -4-  21 
0.1% R.S.  3,754  4-  80  218  -4-  22 
1.0% R.S.  464  -4-  58  257  4-  51 
0.1% J.M.  8,981  4.  384  596  4.  73 
S.O.¶ cells  1%J.M.  7,192  4.  201  610  4.  64 
1% R.S.  552  4-  58  514  4.  56 
1% S.O.  198  ±  34  533  4.  40 
* 200,000 lymphocytes per 0.2 ml culture. 
25,000 HeLa cells (blocked with mitomycin-C) per 0.2 ml culture. 
§ Normal adult human volunteer. 
I[ Measles sero-negative donor. 
¶ SSPE patients. 
TABLE VII 
Inhibition of Rdease of Lymphotoxin by Lymphocytes  from Patients with SSPE in Response to 
SSPE Virus Infected HeLa Cells in the Presence of SSPE Plasma 
Supernatant from:* 
SSPE cells +  SSPE-infected HeLa cells 
Normal cells§ +  SSPE-infected HeLa cells 
SSPE cells +  SSPE-infected HeLa cells 
Normal cells +  SSPE-infected HeLa cells 
Plasma source (10%) 
SSPE plasma 
SSPE plasma 
Normal plasma§ 
Normal plasma 
Lymphotoxin 
level:~ (IDso) 
HeLa  cells  L cells 
0  0 
° 
1  2  1:32 
0  0 
* Supernatant fluid from cultures of lymphocytes (2  X  106/ml)  and SSPE virus infected 
HeLa cells (50,000 cells/ml) after 66 h of incubation at 37°C in a 5% CO2, 95% air humidi- 
fied atmosphere. 
:~ IDso level of lymphotoxin calculated  to  be the dilution of lymphotoxin that showed 
50% reduction in the uptake of [8H]thymidine by L cells or HeLa cells. 
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incubated at 45°C  or 56°C for varying periods of time. As is seen  in Fig.  3, 
the blocking factor was inactivated by heating at 56°C for greater than  20, 
rain. Plasma from SSPE patients stored at -20°C for greater than 6 mo still 
retained its activity in blocking the in vitro release of MIF. 
When plasma from SSPE patients was treated with various enzymes, it was 
found (Table VIII) that it was sensitive to neuraminadase and trypsin but not 
,21  j 
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FIG. 3.  Effect of temperature on the ability of blocking factor in the plasma from patients 
with SSPE to inhibit the response of SSPE leukoeytes to a purified SSPE virus (1%) suspen- 
sion using the migration inhibition test.  (•--0)  56°C;  (i--i)  45°C. 
to ribonuclease and deoxyribonuclease. The blocking factor was not reduced by 
2-mercapto-ethanol treatment and possessed most of its activity in the 25-50 % 
(NH4)2SO4 fraction. 
Plasma or spinal fluid from the SSPE patients was  applied to a  Sephadex 
G-200 column and fractions collected using 0.1  M  Tris-HC1 buffer at pH 7.4. 
It  can  be seen  (Fig.  4)  that  generally three major fractions were  obtained 
with plasma.  Using markers of known molecular weight, such as hemoglobin, 
cytochrome c, and rabbit IgG, it was determined that the mol wt of peak A 
was greater than 150,000. Tubes under each peak were pooled, concentrated to 
the original volume in each case, and termed peak A, B, and C. These fractions 
were then tested in the migration inhibition test to determine the active frac- AI-IMED  ET  AL.  915 
TABLE VIII 
Effect of Various  Enzymes and Chemical Treatment  on the Ability of Blocking  Factor in Plasma 
from Patients with SSPE to Inhibit the Response  of SSPE Leukocytes  to a Purified 
SSPE Virus Suspension  Using  the Migration Inhibition  Test 
SSPE plasma treated with:  % Migration inhibition* 
Control:~  69.2 
Untreated§  8.7 
Neuraminadase  75.4 
Ribonuclease  26.9 
Deoxyribonuclease  --  3.0 
Trypsin-EDTA  73.9 
2-mercapto-ethanol (0.1 M)  6.3 
Ammonium sulfate (0-25 gm %)  4.3 
Ammonium sulfate (25-50 gm %)  73.5 
Ammonium sulfate (>50 gm %)  -- 10.0 
Average area of migration with antigen 
* % Migration inhibition =  1 -- 
Average area of migration without antigen 
:~ Control had measles sero-negative plasma. 
§ 10% SSPE plasma untreated. 
X  100. 
SSPE  PLASMA 
PEAK C 
I  I 
0.7 
0.6 
0.5 
0  0.4 
~0 
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FIG. 4. Fractionation of plasma from a patient with SSPE by gel filtration with Sephadex 
G-200 (column 3.0 X 60 cm, ascending flow rate 12 ml/h) and 0.1M Tris-HC1 buffer, pH 7.4. 
tion. It is seen in Fig. 5 that peak A  of both the plasma and spinal fluid pos- 
sessed the ability to block the release of MIF from leukocytes of both the SSPE 
patient and the measles sero-positive control. The measles sero-negative con- 
trol did not show any response. 916  BLOCKING  FACTORS  IN  SSPE  PATIENTS 
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FIG. 5.  Migration  inhibition  patterns  of  leukocytes  from  SSPE  patient,  measles  sero- 
positive and measles sero-negative donors in response to  1%  SSPE  virus in the presence of 
10% Sephadex fractions A, B, and C from the plasma and spinal fluid of SSPE patients. 
Blocking  Factor Specificity.--In  order  to  determine  the  specificity of  the 
blocking factor in the plasma of SSPE patients, experiments were performed 
using lymphocytes from donors sensitive to a variety of antigens. Leukocytes 
from the various antigen donors and normal guinea pig macrophages were incu- 
bated with  their donor specific sensitizing antigens in  the presence of either 
10% normal plasma or 10% SSPE plasma.  The direct MIF test was used in 
these experiments and the results showed  (Table IX)  that using  either bac- 
terial or viral antigens,  the SSPE blocking factor was only effective with the 
SSPE leukocytes response to SSPE virus. It did not have any effect on the 
other antigens used. 
DISCUSSION 
Conflicting reports on the cellular immune capacity of patients with SSPE 
have been reported.  Gerson and Haslam  (10)  reported that none of the four 
cases of SSPE that they studied responded to six common skin-test antigens 
which  included measles  antigen.  These cases rejected skin  allografts slowly, 
and  they  did  not  develop skin  sensitivity  to  dinitrochlorobenzene.  Similar 
observations have been reported by Kolar (31). Moulias et al. (14), after study- 
ing 20 cases of SSPE,  reported that  the cell-mediated immunity to antigens 
other than measles was normal in these patients.  These in vitro and in vivo AHMED  ET  AL. 
TABLE IX 
Specificity of the Blocking Factor in the Plasma from Patients with SSPE 
917 
Source of leukocytes 
%  Migration inhibition 
in response to respective* 
antigen~ 
10% Normal  10% SSPE 
plasma  plasma 
SSPE patient 1 
SSPE patient 2 
SSPE patient 3 
Cytomegalovirus-infected  patient 
PPD-sensifive donor 
Histoplasmin-sensitive donor 
Streptokinase-streptodornase-sen  sitive donor 
Tetanus-toxoid-sensitive  donor 
Mumps-sensitive donor 
Vaccinia-sensitive  donor 
69.6  8.1 
70.9  --10.2 
69.1  3.6 
69.2  61.1 
87.8  84.5 
48.4  42.7 
72.6  68.3 
49.0  58.6 
42.0  40.2 
47.4  43.5 
* Respective antigen to which patient was sensitized was used as a predetermined optimal 
concentration. 
% Migration inhibition 
Average area of migration with respective antigen 
=  1  --  X  100. 
Average area of migration without antigen 
results were similar to those obtained by Sharma et al. (32) and others (12, 33). 
However, Moulias  et al.  (14)  reported that  lymphocytes from their patients 
with  SSPE  did  not  respond  to  measles  antigen.  This  observation has  been 
reported by others (15, 34). Contrary to these data,  Mizutani  et  al. (13)  and 
Saunders et al.  (12), report that there was no evidence of impairment of the 
cell-mediated function to measles antigen in patients with SSPE, as judged by 
skin tests and the macrophage migration inhibition test. We have previously 
reported results  (25,  35, 36)  that clearly demonstrate the presence of cellular 
immunity to measles antigen in patients with SSPE. 
The reasons for the discrepancies obtained could be (a) the antigen used for 
skin testing or for in vitro testing; (b) the assay system involved; (c) the stage 
of the disease when testing is done;  (d)  the clinical treatment of the patient 
(immunosuppression) when testing is performed which might obscure results; 
(e) infection of the patient with viral agents other than SSPE virus and other 
medical complications. 
While the measles etiology of SSPE has been documented by several reports 
(6,  37-39),  there have been other reports that suggest that either the SSPE 
virus might be slightly different from measles virus (3, 4, 40, 41) or that there 
are other viruses which might act as helper viruses or their presence is unex- 
plained  (42,  43).  In our preliminary experiments, measles virus vaccine used 
gave inconsistent results. It was only after using SSPE virus preparation that 
consistency was obtained. This, therefore, suggests one of the major sources of 918  BLOCKING  FACTORS  IN  SSPE  PATIENTS 
variation of results obtained from several laboratories. This further amplifies 
the need for a standard virus suspension for use in such in vitro and in vivo 
testing. 
The assumption, therefore, that native measles virus is the major cause of this 
encephalopathy becomes debatable. It is very possible that there are two or 
more types of virus,  the wild type and the SSPE type virus,  and that  they 
probably all belong to the myxovirus group, but  the antigenic variation be- 
tween  them  could  cause  one  to  be  extremely pathogenic.  This  would  also 
account for the cross-reactivity to the measles antigen and subsequent failure 
of the immune response. On the other hand, it is also possible that the measles 
virus is activated by yet another virus, an  arbovirus or  a  papovavirus which 
act as helper viruses by the activation of the infected cell genome after fusion 
with susceptible cells in the presence of a myxovirus. This association of two 
viruses has also been noted in cases of rabies and LCM and other diseases such 
as those produced by Epstein-Barr virus. This would therefore entail a  two- 
step  theory of SSPE where live attenuated measles virus,  when used  as  an 
immunization, can be reactivated by some other  paramyxovirus  or papova- 
virus or arbovirus and change its antigenic structure sufficiently to cause fusion 
of the genome of the measles virus into the DNA of the gliai cells and thereby 
give rise to the encephalopathy. The blocking substance could be produced by 
these superinfected glial cells which release this substance into the spinal fluid 
and which then travel into the vascular system. 
In addition to skin testing with measles antigen, various in vitro assays have 
been employed to determine the cell-mediated immune capability of patients 
with SSPE. Again, variable results have been obtained using the lymphocyte 
transformation and the production of MIF assays. Although direct stimulation 
with the many virus suspensions that we have used gave results that were diffi- 
cult to interpret (4,000 cultures), use of virus-infected cells as stimulating cells 
provided consistent data showing the presence of cellular immunity in these 
patients  (25). The MIF assay gave very consistent results in our laboratory, 
but only using SSPE virus suspensions. Measles sero-positive individuals also 
showed MIF production in response to the SSPE virus; however, there was no 
response of sero-positive lymphocytes to SSPE infected HeLa cells in the trans- 
formation studies.  This dichotomy can be explained by the assumption  that 
either  there  are  different  antigens  involved in  stimulating  the  different re- 
sponses;  that  is,  viral  envelope  antigens  stimulating  MIF  production  and 
viral-induced cell surface antigens  causing lymphocyte blastogenesis, or that 
MIF is a preformed product which  is  released by cells on recognition of ho- 
mologous  sensitizing  antigen  and  lymphocyte  transformation  is  an  active 
process,  whereby presensitized  cells undergo  DNA  synthesis  in  response  to 
specific antigens. The lack of response of lymphocytes from measles sero-posi- 
tive individuals in the tests where lymphocytes were stimulated by virus-in- 
fected cells would seem to indicate nonsensitization of the lymphocytes to the AHMED  ET AL.  919 
cell surface  antigens  induced  in the infected HeLa cells by the SSPE  viral 
genome. MIF was measured at 24 h, whereas blastogenesis was measured  at 
72 h after the contact of viral antigens with sensitized cells. It is possible that 
viruses are neutralized by in vitro interferon production by sensitized lympho- 
cytes and therefore not available for stimulation, whereas using virus-infected 
cells, antigens are so provided that cells do not respond by producing interferon 
but  respond  to  the  antigens  expressed on the infected  cell surface.  Such  a 
difference between in vitro transformation and MIF assays has been previously 
reported by Spitler  et al.  (44) using tobacco  mosaic virus protein  (TMVP). 
Lymphocytes from TMVP-sensitized  animals  produced  MIF in response  to 
isolated peptides from TMVP but did not show any capacity for in vitro stimu- 
lation as measured by the uptake of [14C]thymidine.  They explain their data by 
suggesting that they did not use high enough concentrations  of the peptides or 
that there was low binding capacity of the peptides to lymphoid receptor sites, 
or that to stimulate lymphocyte activation a multivalent antigen may be re- 
quired. Similar differences between lymphocyte transformation and MIF assay 
has been shown by other workers (45, 46). 
Rosenberg  et al.  (47) have demonstrated specific in vitro  transformation 
using sensitized rabbit spleen lymphocytes by suspensions of ultraviolet light- 
inactivated Herpes-Simplex and vaccinia viruses. Similarly, Gerber and Lucas 
(48), using ultraviolet, irradiated, noninfectious  Epstein-Barr virus, were able 
to induce activation in sensitized human lymphocytes. On the other hand, Thur- 
man et al.  (25) could not demonstrate stimulation of sensitized lymphocytes 
using cytomegalovirus  suspensions (CMV), whereas CMV-infected WI-38 cells 
specifically activated the sensitized cells. Thus, depending on the antigen used 
and the assay employed,  certain viruses can be used for in vitro stimulation. 
The other assay performed was the LT assay. Here it appeared  that LT was 
produced by measles sero-positive cells and SSPE cells in the presence of sero- 
negative plasma and that this effect was blocked by SSPE plasma. 
Although cell-mediated immunity against the SSPE  virus could be demon- 
strated by the various assay systems, an important finding of this investigation 
was the demonstration of blocking factors present in the plasma and spinal fluid 
of all SSPE patients studied. The concentration of the blocking factor was found 
to be about 10 times greater in the spinal fluid as compared to the plasma in all 
four SSPE cases studied. It is possible that the blocking factor was made by the 
glial cells of the brain and gradually passed into the vascular system. Others 
have reported the presence of inhibitory factors in the serum and plasma from 
patients with a wide range of disorders  (18, 19,  21,  49-52).  An inhibition of 
lymphocyte transformation to antigens and nonspecific mitogens was found in 
the plasma of one of three SSPE  patients studied by Allen, Oppenheim,  and 
Brody (22). The blocking factor reported here was specific for the response to 
SSPE virus and did not block mitogen or  antigen responses. The possibility 
that the blocking  factor is  hyperimmune levels of  specific antibody in  the 920  BLOCKING  FACTORS IN  SSPE  PATIENTS 
plasma of patients with SSPE cannot be completely ruled out. However, the 
fact that the blocking activity is found in Fraction A of the Sephadex gel chro- 
matography (Fig. 4) of the plasma and that anti C'3 neutralizes the blocking 
activity argues against this possibility. Also the mol wt was found to be greater 
than 150,000. The nonsensitivity to 2-mercapto-ethanol rules out the presence 
of IgM type antibodies as the blocking agent. Preliminary data also show that 
if plasma  of patients  with  SSPE  is  incubated  with  commercially available 
measles virus and centrifuged, and the supernatant fluid examined for blocking 
activity, there is a very slight decrease in blocking ability. This still does not 
rule out the possibility that there is an antigenic difference between the com- 
mercially available measles virus and the SSPE virus and that the antibody is 
directed against that specific SSPE antigen. Further studies are currently being 
undertaken to further define the nature of this blocking factor. 
It is difficult to  determine if the blocking factor present in patients with 
SSPE occurs before the disease or one of the manifestations of the disease. The 
only way this can be determined is by animal models and, to date, the models 
which have been successfully used have been ferrets (53), hamsters (54), calves, 
and lambs (55). The investigators employing these models have as yet not ad- 
dressed themselves to the immunological implications (56). The importance of 
blocking factors and their role in the immunological response of lymphocytes 
from patients with a wide group of disorders, including hepatitis, multiple sclero- 
sis,  cancer,  and  slow  virus  diseases  such  as  Kuru,  Jacob-Kreutzfeldt,  etc., 
remains to be elucidated. 
SUMMARY 
Conflicting reports on the immune responsiveness of patients with subacute 
sclerosing panencephalitis (SSPE) have been reported. This report shows that 
the leucocytes from four SSPE patients exhibited strong sensitivity to both 
measles and SSPE virus preparations as measured by the macrophage migra- 
tion inhibition test, mixed lymphocyte virus infected cell culture test, and the 
lymphotoxin assay. Earlier suggestions that a factor may be operating to sup- 
press cellular reactivity are confirmed by the demonstration that the response 
of lymphocytes from SSPE patients could be blocked by the addition of SSPE 
spinal fluid or plasma. It was determined that the blocking factor was stable at 
-20°C, heat labile at 56°C for 30 minutes, trypsin and neuraminadase sensi- 
tive, and had a mol wt greater than 150,000 as determined by Sephadex G-200 
gel chromatography. The blocking factor appeared to be specific for SSPE virus 
and did not block the response of lymphocytes to nonspecific mitogenic agents 
and other viral and bacterial agents. 
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